Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
NCT ID: NCT06992440
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE2
78 participants
INTERVENTIONAL
2025-06-26
2030-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Empagliflozin
Participants receive Empagliflozin 10 mg orally once daily for 24 weeks. Empagliflozin is over-encapsulated to match placebo.
Empagliflozin 10 MG
10 mg tablet once daily
Placebo
Participants receive placebo tablet over-encapsulated to match Empagliflozin orally once daily for 24 weeks.
Placebo
matching tablet once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Empagliflozin 10 MG
10 mg tablet once daily
Placebo
matching tablet once daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Provision of signed and dated informed consent form
2. Ability and stated willingness to comply with all study procedures and availability for the duration of the study
3. Ability to read and write in English
4. Male or female, aged 18 years or older, with group 1 PAH, idiopathic, heritable, associated with drugs and toxins, associated with connective tissue disease and with congenital heart disease (simple repaired or unrepaired defects) according to the current guidelines and adjudicated by the local PI
5. PAH confirmed by right heart catheterization in the last 5 years
6. RV dysfunction defined FAC ≤ 34.0% on echocardiography performed during the screening visit. In PVDOMICS, FAC has a strong correlation with CMR RV ejection fraction, and FAC \< 34% predicts a CMR RV ejection fraction \<37% with a large c-statistic of 0.9. CMR RV ejection fraction \<37% is strongly associated with increased mortality and classifies PAH as high risk under the current guidelines. We do not expect this will curtail recruitment as the mean FAC in the PVDOMICS cohort is 30 ± 10%, a population like the one that will be enrolled in this study.
7. On FDA-approved PAH-targeted therapy (any combination including infused prostacyclin analogues and sotatercept) with stable doses for at least 8 weeks or 24 weeks for sotatercept prior to the screening visit and no clinical plans to change this therapy
8. Diuretic doses stable for at least 4 weeks prior to screening. After screening, diuretic doses may be changed as directed by the site PIs and/or the treating physician.
9. Ability to take oral medication and willingness to adhere to the study drug regimen.
10. For females of reproductive potential: use of highly effective contraception for at least 4 weeks prior to screening and agreement to use such a method during study participation and for an additional 2 weeks after the end of study drug administration
11. Able to have baseline and week 24 CMR according to Imaging Core criteria, as adjudicated by the Site PI
Exclusion Criteria
1. Current use of insulin, insulin secretagogues (sulfonylureas and meglitinides), lithium or an SGLT2 inhibitor
2. Use of an SGLT2 inhibitor within the past 3 months prior to screening
3. Prior documented inability to tolerate an SGLT2 inhibitor
4. Volume depletion, as ascertained by the site PI, at screening or baseline
5. History of diabetic ketoacidosis or type 1 diabetes mellitus
6. Chronic alcohol or drug abuse
7. More than one bacterial or yeast genitourinary tract infection in the year prior to enrollment
8. Estimated glomerular filtration rate under 30 mL/minute/1.73m2 or on renal replacement therapy
9. Pregnancy or lactation
10. Known allergy or hypersensitivity to empagliflozin or another SGLT-2 inhibitor
11. Currently taking or has taken another investigational drug within the past 4 weeks
12. Enrollment in another randomized intervention trial. (Participants participating in observational trials will not be excluded).
13. Decompensated right heart failure, as adjudicated by the site PI.
14. Screening HbA1c \>10% with symptoms such as polyuria and polydipsia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Cleveland Clinic
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Gustavo A Heresi, MD, MS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gustavo A Heresi, MD, MS
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gustavo Heresi, MD
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Johns Hopkins Hospital
Baltimore, Maryland, United States
Cleveland Clinic
Cleveland, Ohio, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.